CD19 and acute lymphoblastic leukemia: Other early studies of CD19 CAR-T therapy in children and young adults with R/R B-ALL have shown similar CR rates of 70–96% and attainment of MRD-negative remission in a majority of responders (60–93%), as well as similar EFS and OS [41,42].